Search results
Sir James Whyte Black OM FRS FRSE FRCP (14 June 1924 – 22 March 2010 [2]) was a Scottish physician and pharmacologist. Together with Gertrude B. Elion and George H. Hitchings, he shared the Nobel Prize for Medicine in 1988 for pioneering strategies for rational drug-design, which, in his case, lead to the development of propranolol and cimetidine.
Sir James Black (born June 14, 1924, Uddingston, Scot.—died March 21, 2010) was a Scottish pharmacologist who, along with George H. Hitchings and Gertrude B. Elion, received the Nobel Prize for Physiology or Medicine in 1988 for his development of two important drugs, propranolol and cimetidine.
- The Editors of Encyclopaedia Britannica
Mar 23, 2010 · Dr. James W. Black, a Scottish pharmacologist whose discovery of beta blockers and another class of drugs extended the lives of millions of people with heart and stomach disorders and...
He illuminated the black box between drug delivery and effect, developing analytical methods for estimating the levels and tissue distribution of a drug and its metabolites which allowed us to monitor and control toxicity tests, human pharmacology and clinical trials.
Apr 1, 2010 · James Black, Jim to his many friends and colleagues, shared the Nobel Prize in Physiology or Medicine in 1988 for pioneering research that led to two new classes of drug. Adrenergic β-blockers...
- Robin Ganellin, William Duncan
- 2010
Nov 11, 2020 · James Whyte Black was a Scottish pharmacologist who trained in medicine at St Andrews University and had a career in drug invention and academic pharmacology, moving several times between universities and the pharmaceutical industry.
People also ask
Who was Sir James Whyte Black?
How did John Black become a pharmacologist?
How did James Whyte Black influence pharmacology?
Who was Sir James Black?
Sir James Black was appointed as professor of pharmacology at King’s in 1984 and retained connections with the college for the rest of his life. He was awarded the Nobel Prize in Physiology or Medicine in 1988 for the development of two major families of drugs.
